Point72 Hong Kong’s Cardiff Oncology CRDF Stock Holding History

Point72 Hong Kong’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,154	Closed	-$5K	–	1996
2022 Q1	$5K	Buy	+2,154	New	+$7.62K	﹤0.01%	1676

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Point72 Hong Kong's CRDF Position: Q2 2022 in Review

Point72 Hong Kong sold out of Cardiff Oncology (CRDF) in Q2 2022, closing a stake of 2,154 shares — an estimated $5K sold.

Point72 Hong Kong first reported a position in CRDF in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 67 funds tracked by Wall St. Rank hold CRDF as of Q2 2022.

Point72 Hong Kong reported no remaining Cardiff Oncology position as of Q2 2022 after selling out during the quarter.
Point72 Hong Kong sold 2,154 Cardiff Oncology shares in Q2 2022, an estimated $5K.
Point72 Hong Kong first reported a position in Cardiff Oncology in Q1 2022 and held it in 1 quarter.
Point72 Hong Kong's Cardiff Oncology position peaked at $5K in Q1 2022.
67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.